Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | A two-year analysis of the EBMT-SAAWP RACE trial: eltrombopag in aplastic anemia

Antonio Risitano • 16 Apr 2024
EBMT 2024
Anemias Aplastic Anemia Cyclosporine Eltrombopag Horse antithymocyte globulin
Race

Antonio Risitano, MD, PhD, AORN San Giuseppe Moscati Di Avellino, Avellino, Italy, presents a two-year analysis of the EBMT-SAAWP RACE study investigating eltrombopag in the treatment of aplastic anemia. The study shows that adding eltrombopag to immunosuppressive regimens significantly improves outcomes. This establishes eltrombopag in combination with antithymocyte globulin (ATG) and cyclosporine as a new standard of care (SoC) for aplastic anemia. Longer-term follow-up is ongoing. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Antonio Risitano

7:15
Is alloSCT a suitable treatment option for older patients with aplastic anemia?
Antonio Risitano • 16 Apr 2024
3:42
Aplastic anemia: treatment options in 2019
Antonio Risitano • 26 Oct 2019
2:29
Unrelated transplantation vs. immunosuppression for SAA
Antonio Risitano • 25 Oct 2019

Related Videos

3:01
Recent advancements in the treatment of aplastic anemia
Simona Pagliuca • 24 Apr 2024
7:15
Is alloSCT a suitable treatment option for older patients with aplastic anemia?
Antonio Risitano • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:31
Mitapivat improves work/school attendance in patients with pyruvate kinase deficiency
Hanny Al-Samkari • 9 Dec 2023
The content of VJHemOnc is intended for healthcare professionals